Narcolepsy type 1 (Na-1) and 2 (Na-2) are characterized by an inability to sustain wakefulness and are likely caused by degeneration of orexin neurons. Near complete orexin neurodegeneration depletes orexin-A from the cerebrospinal fluid and produces Na-1. The pathophysiology of Na-2 is less understood, but has been hypothesized to be due to less extensive loss of orexin neurotransmission. The orexin-tTA; TetO diphtheria toxin A mouse allows conditional control over the extent and timing of orexin neurodegeneration. To evaluate partial ablation of the orexin field as a model of Na-2, orexin-A positive cell counts and sleep/wake phenotypes (determined by piezoelectric monitoring) were correlated within individual mice after different protocols of diet-controlled neurodegeneration. Partial ablations that began during the first 8 days of study were 14% larger than partial ablations induced during the last 8 days of study, six weeks later and prior to sacrifice of all mice, suggesting orexin-A positive cell death continued despite the resumption of conditions intended to keep orexin neurons intact. Sleep/wake of mice with 71.0% orexin-A positive cell loss, initiated at the beginning of study, resembled that of orexin-intact controls more than mice with near complete neurodegeneration. Conversely, mice with 56.6% orexin-A positive cell loss, created at the end of study, had sleep/wake phenotypes that were similar to those of mice with near complete orexin-A positive cell loss. Collectively, these results suggest that compensatory wakepromotion develops in mice that have some critical portion of their orexinergic system remaining after partial ablation.
Introduction
The sleep disorder narcolepsy features excessive daytime sleepiness (EDS), rapid-eyemovement (REM) sleep abnormalities, disturbed nighttime sleep, and is caused by diminished orexin (also known as hypocretin) neurotransmission. 1 Insufficient orexin-A levels in the cerebrospinal fluid (CSF) are thought to be due to autoimmune-related destruction of the sole population of neurons that produce orexin. [2] [3] [4] Patients with narcolepsy type 1 (Na-1) have low CSF orexin-A levels, cataplexy (a sudden, reversible loss of muscle tone triggered by emotions), or both. Narcolepsy type 2 (Na-2) is based on exclusion of Na-1 criteria, and its etiology is less understood than the pathology underlying narcolepsy with cataplexy. However, a limited postmortem study suggests Na-2 can be caused by 33% orexin cell loss vs. the ~90% loss observed in patients with Na-1. 5 Levels of CSF orexin-A that are between normal and the Na-1 cutoff value have been associated with Na-2 in a subset of patients. 6, 7 Both types of narcolepsy are diagnosed, in part, by EDS that is determined by the inability of patients to sustain long periods of wakefulness during the Maintenance of Wakefulness Test (MWT) and to fall asleep with short latency on the Multiple Sleep Latency Test (MSLT).
Two transgenic mouse models have been created that recapitulate the orexin neurodegeneration and arousal state boundary dysregulation observed in Na-1. The orexin/ataxin-3 (Atax) mouse exhibits constitutive, postnatal loss of 80-99% of orexin neurons [8] [9] [10] [11] and express a range of narcolepsy symptom severity. 1 The orexin-tTA; TetO diphtheria toxin A (DTA) mouse uses the double transgenic Tet Off (TetO) system to allow conditional ablation of orexin neurons. 12 Administration of doxycycline (DOX) to these mice blocks the tetracycline transactivator from binding to the TetO binding site and disables the expression of the DTA neurotoxin. Thus, orexin neurodegeneration can be induced by removal of doxycycline (DOX(-)). Withdrawal of dietary DOX (100 μg/g chow) for 1.5, 3.5, 7, 14 and 28 days followed by resumption of DOX has been shown to induce 36%, 64%, 86%, 95%, and 97% orexin cell loss, respectively. 12 Longitudinal study by the same research group on a different set of DTA mice on continual DOX(-) has shown fragmentation of wakefulness during the dark period at 1 week DOX(-) that progressively worsened over the next 3 weeks. During this time, cataplexy began at 2 weeks DOX(-) and increased in frequency over the next 5 weeks or more. Thus, conditional control of orexin neurodegeneration in DTA mice has been proposed to model either Na-1 or Na-2, depending on the extent of the ablation. However, to validate partial ablation of the orexin field as a model of Na-2, the precision of the DOX(-) timing to reliably induce a certain percentage of orexin cell loss that corresponds to a translatable phenotype of Na-2, all within the same animal, must be determined.
Recently, a translational test of the ability to sustain long bouts of wakefulness has been developed for mice using piezoelectric monitoring of sleep/wake. 13 The PiezoSleep narcolepsy screen measures the ratio of time spent in long (≥ 32 min) wake bouts to time spent in short (< 8 min) sleep bouts to yield a "wake maintenance score." Sleep/wake is sampled during the first half of the dark period, when sustained wakefulness predominates in wild type mice, to allow narcolepsy symptom severity to be assessed.
Here, orexin cell counts and sleep/wake phenotypes were correlated within individual DTA mice after partial ablation of the orexin neuronal field and sex differences were determined.
The effectiveness of the Tet Off system to maintain intact orexin neurons after partial ablations induced by DOX(-) was evaluated. The stability of the sleep/wake phenotypes over time that correspond to different orexin neurodegeneration protocols were also assessed. These results further define the parameters that are essential to the validate the DTA model beyond Na-1.
Materials and Methods
All experimental procedures were approved by the Institutional Animal Care and Use Committee at Reset Therapeutics and were conducted in accordance with the principles set forth in the Guide for Care and Use of Laboratory Animals.
Animals. Male and female orexin-tTA mice were bred with B6.Cg-Tg(tetO-DTA)1Gfi/J mice (both strains from Nagoya University, Nagoya, JP) to produce orexin-tTA; TetO diphtheria toxin A (DTA) mice that were hemizygous for both transgenes. 12 Male and female C57BL/6NTac were used as wild type (WT) controls in Study 1. All DTA and WT mice were bred at Taconic Biosciences, Hudson, NY. All breeders and DTA mice were given doxycycline (DOX) chow (200 μg/g chow, TD.98186, Envigo, Madison, WI), to deliver a daily dose of approximately 0.6 mg DOX, until they were switched to standard chow at the start of experimental orexin neurodegeneration. Male and female hemizygous transgenic B6.Cg-Tg(HCRT-MJD)1Stak/J mice (Atax) and wild type (WT) littermates (JAX stock #023418, Jackson Labs, Bar Harbor, ME) were used in Study 2 as comparator groups that represent a standard model of narcolepsy 8 In study 2 (Figure 1 ), the relationship between the size and timing of partial ablation of the orexin neuronal field and sleep/wake phenotype was determined. Twenty-five DTA mice were randomly assigned into groups based on DOX diet schedule; males and females were represented across groups and individually housed upon arrival for the duration of study. Mice Figure 1 . Study 2 protocol. Orexin/tTA; TetO diphtheria toxin A (DTA) colony mates were randomly assigned into study groups based on targeted orexin neuronal field ablation size and timing; males and females were represented across groups. DTA mice were either (1) maintained on doxycycline for 7 weeks (DOX(+)7wk) to keep orexin neurons intact (N = 2 males, 2 females), (2) subjected to removal of doxycycline for 8 days and resumption of DOX(+) for 6 wk (DOX(-)8d (RD)6wk) to induce partial orexin neurodegeneration during the first study week (N = 4 males, 2 females), (3) subjected to removal of doxycycline 8 days prior to sacrifice (DOX(+)6wk DOX(-)8d) to induce partial orexin neurodegeneration during the last study week (N = 4 males, 3 females), or (4) maintained without doxycycline for 7 weeks (DOX(-)7wk) to induce full orexin neurodegeneration (N = 4 males, 4 females). Sleep/wake was measured by piezoelectric monitoring at study weeks 4 and 7. For each sleep/wake recording, mice were moved from home cage to PiezoSleep cage for 20-24 h acclimation followed by experimental sampling for 30-48 h. At the end of the recording on study week 7, mice were sacrificed for histology. sections were incubated for 2 hours at room temperature with biotinylated donkey anti-goat (Jackson Immunoresearch, West Grove, PA) at 1:500 dilution in blocking solution. After further washes, sections were developed with the avidin-biotin-peroxidase system using diaminobenzidine as the chromagen (Vector Laboratories, Burlingame, CA). Sections were mounted onto slides, and anatomically matched sections between brains that represented the anterior, mid, and posterior regions of the orexin field, approximately -1.4, -1.5, and -1.6 mm from Bregma, respectively, were identified for cell counting. A 1.4 mm 2 counting box was delimited 0.3 mm from midline and 0.2 mm dorsal to the base of the 3 rd ventricle. Counts were performed bilaterally on these sections using Fiji Image J automated for thresholding and particle analysis of positively stained objects using a watershed filter and a measure of circularity on a 0 to 1 scale. Comparison of manual counts vs. automated counts on brains from WT and DTA mice with either no or partial ablation indicated 96-99% agreement.
Disagreements mostly resulted from a few cells missed by automated counts because of overlapping somas. Immunohistochemistry for orexin-A on free-floating brain sections and manual cell counting methods for Atax mice (N = 13) and WT littermates (N = 14), aged 16.9 ± 0.1 and 28.5 ± 0.8 g, have been previously described. 13 Sleep/wake recordings. In Study 2, the sleep phenotype of DTA mice with intact, partial, and full ablations of the orexin neuronal field were determined by piezoelectric recording of gross body movement and breath rate (PiezoSleep version 2.11, Signal Solutions, Lexington, KY). By capturing a detailed respiratory measure in addition to locomotor activity, the highly sensitive piezo sensor enables quiet wakefulness to be distinguished from sleep using relevant physiology. [14] [15] [16] [17] The PiezoSleep apparatus consisted of individual polycarbonate cages, each of which contained a polyvinylidene difluoride piezo sensor beneath a thin plastic shield. The sensor covered the entire area of the cage floor and was connected to a single channel tube amplifier (RoMo version 1.2, Signal Solutions, Lexington, KY). Each amplifier fed into a digital acquisition device connected to a computer for data collection and sleep/wake determination as previously described. 14, 15, 17 Briefly, signals were amplified and filtered between 0.5 and 10 Hz and analog-to-digital converted at 120 Hz sampling rate. The frequency, amplitude, and peak spectral energy of the signal were evaluated in 2 second increments over a tapered, 8 second window to automatically calculate a sleep/wake decision statistic by simple linear discriminant analysis. Sleep was classified if signals exhibited a periodicity with a consistent, low relative amplitude at a frequency in the typical breathing range (1-4 Hz). Wakefulness was associated with high amplitude signals with variable frequency and broad spectral energy. Signal features related to these properties were extracted and combined to obtain a decision statistic for each interval. Over time, the decision statistics per increment accumulated in a bimodal distribution, and the saddle point of the distribution was determined using an adaptive threshold for the classification of sleep and wake. Bouts of contiguous intervals of sleep or wake were defined to terminate when an interval, equal to the minimum bout length of 30 s, included less than 50% of the targeted state. This method of automated, unsupervised classification of sleep/wake by piezoelectric monitoring in mice has an accuracy of 90% vs. manual EEG scoring 17 and has been used to characterize the sleep/wake phenotype of numerous transgenic mouse lines, including models of neuropathology with sleep fragmentation 18, 19 and the unconsolidated sleep/wake of narcoleptic Atax mice. 13 Piezoelectric experiments began by loading mice into individual PiezoSleep cages that For the PiezoSleep narcolepsy screen, the relationship between time spent in long WBD and short SBD was determined using Pearson correlation, and the ratio of these variables (long WBD:short SBD, i.e., wake-maintenance score) vs. orexin-A positive cell counts, was determined using Spearman correlation (unequal variance for cell counts). Comparison of the long WBD:short SBD ratio between DOX groups was made using one-way ANOVA. Pearson correlations were used to evaluate the stability of sleep measures (daily sleep amount, time in long WBD, time in short SBD, long WBD:short SBD) between Study Weeks 4 and 7. For each analysis in which significance was indicated (α = 0.05), contrasts between relevant factor levels (genotype/DOX chow status, sex, or time bin, as appropriate) were detected post hoc with Bonferroni's multiple comparisons test (for ANOVA), or multiple comparisons were corrected by controlling the False Discovery Rate using the two-stage step-up method (for Kruskal-Wallis). resembled Atax mice (96.6 % cell loss, Figure 4B ) and exhibited a lower wake-maintenance score than DTA mice maintained on DOX(+) with intact orexin neurons ( Figure 4C) Figure 5B ), in SBD < 8 min ( Figure 5C ), and the ratio of these variables ( Figure   5D ) also strongly correlated between Study Weeks 4 and 7.
Results

Histology
Discussion
For the first time, sleep/wake phenotypes and orexin-A positive cell counts have been determined in the same individual DTA mice after partial ablation of the orexin neuronal field and sleep/wake measurement by piezoelectric monitoring. First, the effect of animal shipment An important factor relevant to the interpretation of the neurodegeneration results in the current study vs. previous work concerns the different concentrations of DOX chow employed.
In Study 1, DOX(-)2d resulted in ~5x less orexin-A positive cell loss than anticipated based on the rate of neurodegeneration previously reported. 12 Doxycycline in the current study was provided at twice the concentration as was used previously for an estimated daily dose of 24 mg/kg. An approximately 10-fold lower daily dose of DOX, as supplied by DOX (10 μg/mL) in drinking water, has been recommended as the optimal concentration for manipulation of gene expression within 1-2 days using the TetO system due to the very slow kinetics of washout and reactivation of the transgene. 22 Although the pharmacokinetics of DOX used in the current study is unknown, the dose used was ~16-fold lower than the dose achieved with DOX (2 mg/mL), which has been shown to cause residual suppression of gene expression after 8 weeks washout. 23 In the current study, the smaller than expected ablation sizes and the continued neurodegeneration that was observed for weeks past the resumption of DOX may be related to the slow clearance of the DOX (200 μg/g) diet.
Orexin insufficiency to varying degrees, as measured through either CSF orexin-A levels or postmortem histology, has been associated with a variety of neurological conditions in addition to narcolepsy and expands the clinical relevance of the DTA mouse. Orexin cell loss of 27% in Huntington's disease, 24 23-62% in Parkinson's disease, 25, 26 and 69% in multiple system atrophy 27 has been demonstrated despite normal levels of CSF orexin-A in these patient populations. [28] [29] [30] [31] This discrepancy suggests that the residual orexin neurons compensate for reduced orexin connectivity with increased peptide release. Compensation has been observed in rats with hypothalamic orexin-B-saporin lesions; 73% orexin cell loss resulted in only 50% loss of CSF orexin-A. 32 If this relationship can be extrapolated to DTA mice, then it can be speculated in the current study that mice with partial ablations may have had CSF orexin-A levels that were 40-50% less than those in orexin-intact controls. DTA mice with ≥ 97% orexin neurodegeneration may have had ≥ 66% loss of CSF orexin-A. This level of remaining CSF orexin-A (~1/3 of orexin-intact controls) is very close to the cutoff value (30% of controls or 110 pg/mL) that is most predictive of narcolepsy with cataplexy in the human diagnostic test. 7 Future research to test these relationships between orexin cell loss and CSF orexin-A levels, and thereby increase the translational value of the partially ablated DTA mouse, will require the development of a highly sensitive assay to detect orexin-A levels in small volume (10 μL) CSF samples from individual mice, as current assays require pooling samples to obtain 5x that volume. 9 Narcolepsy type 2 is a heterogeneous disease entity with uncertain pathophysiology that makes clinical diagnosis and animal modeling challenging. Diagnosis of Na-2 requires: EDS, a positive score on the MSLT (sleep latency ≤ 8 min, and ≥ 2 sleep onset REM periods), an absence of cataplexy, and differentiation from idiopathic hypersomnia by signs of REM sleep boundary dysregulation. 33 The majority of patients with Na-2 have normal CSF orexin-A levels, 7 but 8% of patients with narcolepsy without cataplexy were found to have intermediate CSF orexin-A levels that were above the Na-1 cutoff value and below the normal level of ≥ 200 pg/mL. 34 Seven out of 10 patients with intermediate CSF orexin-A levels were found to have atypical or no cataplexy. 6 In patients with intermediary orexin-A levels, 18% developed cataplexy years after the original narcolepsy-without-cataplexy diagnosis. 34 These data, together with the intermediary number of orexin cells found postmortem from one patient with narcolepsy without cataplexy, 5 support the hypothesis that at least some cases of Na-2 lie on a continuum between Na-1 and idiopathic hypersomnia. The current study offers the first steps toward development of a mouse model of Na-2 based on this hypothesis that partial disruption of orexinergic signaling results in pathological sleepiness associated with less severe narcolepsy. However, the current study is limited by the lack of cataplexy and REM sleep measurements. Cataplexy assessment would be necessary to fully differentiate whether the phenotypes observed in DTA mice with partial ablations of the orexin field translate as Na-1 or Na-2. REM sleep timing may further distinguish subtle differences between DTA mice with different sizes of partial ablations. Measuring cataplexy requires invasive, time-consuming, and expensive procedures, and as such, would be the next step after establishment of protocols for creating specific ablation sizes that are associated with the mouse equivalent of excessive daytime sleepiness.
In conclusion, a sub narcoleptic phenotype was modeled in DTA mice to the extent that a range of wake-maintenance scores was found to be associated with different sizes and durations of orexin-A positive cell loss. The relationship between partial orexin neurodegeneration and sleep/wake phenotype depends on the dynamics of progressive orexin cell loss and the development of a compensatory wake response. Further work is recommended to titrate the DOX(-) RD protocol for the induction of stable 80-90% orexin neurodegeneration.
This amount of orexin cell loss is predicted to distinguish partially ablated DTA mice from orexinintact controls without permitting cataplexy. The establishment of a mouse model based on partial ablation of orexin neurons will be critical for efficacy tests of orexin modulator therapies for narcolepsy and other diseases characterized by orexin insufficiency. 
